J. Massengill

Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.

M. Butler, G. Talaska, F. Kadlubar, 1990, Progress in clinical and biological research.

The identification of [2-(14)C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine metabolites in humans.

K. Turteltaub, K. Kulp, M. Knize, 1999, Carcinogenesis.

Validity of an ELISA for N-acetyltransferase-2 (NAT2) phenotyping.

B. Leyland-Jones, P. Wong, K. Banerjee, 2001, Journal of immunological methods.

In vivo human metabolism of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).

K. Turteltaub, K. Kulp, M. Knize, 1999, Cancer letters.

Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.

R. Hayes, P. Vineis, M. Butler, 1992, Pharmacogenetics.

Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps.

M A Butler, M. Butler, M. Hauer-Jensen, 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5-b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved.

R. Tukey, C. Strassburg, T. Tephly, 1999, Carcinogenesis.